

Date: 12th November, 2022
To, Listing Department,
BSE Limited,
Floor 25, PJ Tower Dalal Street,
Mumbai - 400 001
Script Code: 540359

Sub.: Outcome of the meeting of the Board of Directors of the Company

Dear Sirs,

In continuation of our Corporate announcement dated 5th November, 2022 we hereby inform you that the Board of Directors of the Company has, at its meeting held today, inter—alia, considered and approved the attached Unaudited Financial Results for quarter and half year ended 30th September, 2022. The same has also been reviewed by the Audit Committee in its meeting held today. A copy of the Statement of Unaudited Financial Results for the quarter and half year ended 30th September, 2022.

Further we are submitting the Limited Review report on Unaudited Financial Results for quarter and half year ended 30th September, 2022 issued by our Statutory Auditors i.e. M/ s. BA Shah S R Mehta & Co.

The meeting was commenced at 12.30 pm and was concluded at 2:00 pm.

Kindly take this on your records. Thanking you,

Yours faithfully,

For, Parmax Pharma Limited

YASH
JAYESHBHAI
VORA

Digitally signed by YASH
JAYESHBHAI VORA
Date: 2022.11.12
14:15:41 +05'30'

Yash Vora
Company Secretary

Statement of Standalone Unaudited Results for the Quarter & Half year ended 30.09.2022							
							(in Rs. Thousands)
Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from operations	21338.18	15553.55	65424.43	36891.73	82772.63	182511.20
II.	Other income	77.21	84.00	246.52	161.21	404.10	627.81
III.	Total Income (I+II)	21415.39	15637.56	65670.94	37052.94	83176.72	183139.01
IV.	Expenses						
	(a) Cost of materials consumed	4923.70	12801.91	13679.20	17725.61	21789.48	67179.40
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	3405.12	-7995.62	11047.51	-4590.51	1785.55	-61.00
	(d) Employee benefits expense	5121.32	5481.06	12021.93	10602.38	20140.90	34616.07
	(e) Finance Costs	1170.99	914.05	994.18	2085.04	1927.64	3858.12
	(f) Depreciation and amortisation expense	4666.53	4614.08	4768.28	9280.61	9477.61	19320.89
	(g) Other expenses	9153.53	13002.97	11753.58	22156.50	21000.14	55192.82
	Total expenses (IV)	28441.19	28818.45	54264.67	57259.64	76121.32	180106.31
V.	Profit/(Loss) from operations before exceptional items and tax (I-IV)	-7025.81	-13180.89	11406.27	-20206.70	7055.40	3032.70
VI.	Exceptional Items	0	0	0	0	0	0
VII.	Profit/ (Loss) before tax (V-VI)	-7025.81	-13180.89	11406.27	-20206.70	7055.40	3032.70
VIII.	Tax expense:						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	2250.00
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	632.43
IX.	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	-7025.81	-13180.89	11406.27	-20206.70	7055.40	1415.13
X.	Profit/(loss) from discontinued operations		0				
XI.	Tax expense of discontinued operations	0	0	0	0	0	0
XII.	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0	0	0	0	0	0
XIII.	Profit (Loss) for the period (IX+XII)	-7025.81	-13180.89	11406.27	-20206.70	7055.40	1415.13
XIV.	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0	0	0	0	0	0
	B. (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV.	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	-7025.81	-13180.89	11406.27	-20206.70	7055.40	1415.13
XVI.	Paid-up equity share capital (Face Value Rs 10)	37413.00	37413.00	37413.00	37413.00	37413.00	37413.00
XVII.	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each):						
	(a) Basic (In Rs)	-1.88	-3.52	3.05	-5.40	1.89	0.38
	(b) Diluted						

Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 12.11.2022
 2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and half year ended 30th September, 2022
 3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
 4. Statement of Unaudited Financial Results of the company for the Quarter and half ended 30th September, 2022 in the prescribed format under Schedule III of Companies Act, 2013
 5. The figures for the previous period have been regrouped wherever necessary.
- * The Company has decided to gradually write off its all Preliminary and Pre-operative expenses which are forming the part of Balance Sheet accordingly Company has written off Rs. 9,90,350/- during this quarter under review and it is forming part of Other Expenses.

Place: Rajkot
Date: 12.11.2022

FOR, PARMAX PHARMA LIMITED

UMANG
ALKESH
GOSALIA

Digitally signed by UMANG
ALKESH GOSALIA
Date: 2022.11.12 14:10:46
+05'30'

Dr. Umang Gosalia
Managing Director

(Amt. Rs. In Thousands)

STATEMENT OF ASSETS AND LIABILITIES AS AT 30.09.2022			
Sr. No.	Particulars	As at 30.09.2022 (Unaudited)	As at 31.03.2022 (Audited)
I.	Assets		
1	Non-current assets		
	(a) Property, Plant and Equipment	100304.37	104426.54
	(b) Capital work-in-progress	0.00	0.00
	(c) Investment Property	0.00	0.00
	(d) Goodwill	0.00	0.00
	(e) Other Intangible assets	0.00	0.00
	(f) Intangible assets under development	0.00	0.00
	(g) Biological Assets other than bearer plants	0.00	0.00
	(h) Financial Assets	0.00	0.00
	(i) Investments	6.00	6.00
	(ii) Trade receivables	0.00	0.00
	(iii) Loans	3920.84	1795.22
	(i) Deferred tax assets (net)	0.00	0.00
	(j) Other non-current assets	5942.10	7922.80
	Total Non-Current Assets	110173.30	114150.56
2	Current assets		
	(a) Inventories	27765.47	28524.99
	(b) Financial Assets	0.00	0.00
	(i) Investments	0.00	0.00
	(ii) Trade receivables	3057.16	6768.98
	(iii) Cash and cash equivalents	489.12	10542.52
	(iv) Bank balances other than (iii) above	0.00	0.00
	(v) Loans	10737.77	19760.08
	(vi) Others (to be specified)	0.00	0.00
	(c) Current Tax Assets (Net)	0.00	0.00
	(d) Other current assets	4524.67	0.00
	Total Current Assets	46574.18	65596.58
	Total Assets	156747.48	179747.13
II.	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share capital	44511.50	44511.50
	(b) Other Equity	-5118.89	15087.80
	Total Equity	39392.61	59599.30
2	LIABILITIES		
i.	Non-current liabilities	0.00	
	(a) Financial Liabilities	0.00	0.00
	(i) Borrowings	55791.41	45232.48
	(ii) Trade payables	0.00	0.00
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	0.00	0.00
	(b) Provisions		0.00
	(c) Deferred tax liabilities (Net)	1773.60	1773.60
	(d) Other non-current liabilities	0.00	0.00
	Total of Non-Current Liabilities	96957.61	47006.08

ii.	Current liabilities		
	(a) Financial Liabilities	0.00	0.00
	(i) Borrowings	0.00	0.00
	(ii) Trade payables	49044.12	55211.07
	(iii) Other financial liabilities (other than those specified in item (c))	0.00	0.00
	(b) Other current liabilities	3674.46	8594.35
	(c) Provisions	7071.29	9336.33
	(d) Current Tax Liabilities (Net)	0.00	0.00
	Total of Current Liabilities	59789.87	73141.76
	Total Equity and Liabilities	156747.48	179747.13

FOR, PARMAX PHARMA LIMITED

UMANG
ALKESH
GOSALIA

Digitally signed by
UMANG ALKESH
GOSALIA
Date: 2022.11.12
14:11:19 +05'30'

Place: Rajkot
Date: 12.11.2022

Dr. Umang Gosalia
Managing Director

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2022			
(Amt. Rs. In Thousands)			
PARTICULARS	Half Year Period Ended on 30.09.2022	Half Year Period Ended on 30.09.2021	Period Ended on 31.03.2022
	Unaudited	Unaudited	Audited
(A) CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit After Extraordinary Item but Before Taxation:	-20206.70	7055.40	3032.70
Adjustments for:			
Depreciation	9280.61	9477.61	19320.89
Provision for Current Tax	0.00	0.00	2250.00
Provision for Deferred Tax Assets	0.00	0.00	-97.10
Operating profit before Working Capital changes	-10926.08	16533.01	20200.70
Adjustments for changes in Working Capital:			
(Increase) / Decrease in Inventories	759.53	11512.80	11006.41
(Increase) / Decrease in Trade & Other Receivables	3711.83	-26815.42	9773.54
(Increase) / Decrease in Short term Loans and Advances	4497.64	10733.81	2094.43
Increase / (Decrease) in Current Liabilities	-13351.89	-51718.38	-40274.22
Increase / (Decrease) in Tax Provisions	0.00	0.00	960.74
(Increase) / Decrease in Non Current Assets	1980.70	1980.70	3961.40
(Increase) / Decrease in Long term Loans & Advances	-2125.62	-452.83	-228.53
Cash generated from Operations	-4527.81	-54759.33	-12706.23
Net Cash from Operating activities (A)	-15453.90	-38226.33	7494.46
(B) CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of Fixed Assets	-5158.44	-1913.88	-15315.99
Net Cash from / (Used in) Investing activities (B)	-5158.44	-1913.88	-15315.99
(C) CASH FLOW FROM FINANCING ACTIVITIES			
Increase / (Decrease) in other Long Term Borrowings	10558.93	13216.00	-9100.43
(Increase) / Decrease in Non Current Investment	0.00	2000.00	0.00
Net Cash (Used in) Financing activities (C)	10558.93	15216.00	-9100.43
Net Increase in Cash & Cash Equivalents (A + B + C)	-10053.41	-24924.21	-16921.96
Cash & Cash Equivalents at the beginning of the year	10542.52	25464.48	27464.48
Cash & Cash Equivalents at the end of the year	489.11	540.27	10542.52

FOR, PARMAX PHARMA LIMITED

 UMANG ALKESH
 GOSALIA

 Digitally signed by UMANG
 ALKESH GOSALIA
 Date: 2022.11.12 14:11:42
 +05'30'

 Dr. Umang Gosalia
 Managing Director

 Place: Rajkot
 Date: 12.11.2022

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

To
The Board of Directors,
PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter and Six months ended **30th September 2022** ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on **12th November 2022**. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there



Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road

Branch Office:
302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,

Electronic Address:
(O) 0281-2468261
(M) 09427564149

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Rajkot

Date : 12.11.2022



For **B. A. SHAH S R MEHTA & Co.**
Chartered Accountants
FRN NO : 128796W

A handwritten signature in blue ink that reads "Malay B. Shah".

MALAY B SHAH

Partner

M. No. 159526

UDIN : 22159526BCXSAF2032

Head Office:

209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road

Branch Office:

302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,

Electronic Address:

(O) 0281-2468261

(M) 09427564149